GT BIOPHARMA, INC. Operating Lease, Impairment Loss
GT BIOPHARMA, INC. (GTBP) reported Operating Lease, Impairment Loss of $4.60 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2019-11-14
- GT BIOPHARMA, INC. operating lease, impairment loss for the quarter ending 2019-09-30 was $4.60M, a 97.99% decline year-over-year.
- GT BIOPHARMA, INC. operating lease, impairment loss for the quarter ending 2018-09-30 was $228.51M.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 9 month |
|---|---|---|
| 2019-09-30 | $4.60M 10-Q · filed 2019-11-14 | $4.60M 10-Q · filed 2019-11-14 |
| 2018-09-30 | $228.51M 10-Q · filed 2019-11-14 | $228.51M 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |